Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma.
Warburg effect
apoptosis
caspase pathway
inhibitor of apoptosis proteins
stemness maintenance
testicular teratoma
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
17
09
2020
accepted:
23
06
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
23
10
2021
Statut:
ppublish
Résumé
Inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans that physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. Melanoma IAP (ML-IAP) is a potent anti-apoptotic protein that is strongly upregulated in melanoma and confers protection against a variety of pro-apoptotic stimuli. In the present study, it was revealed that ML-IAP was expressed at high levels in testicular teratoma. Deletion and mutational analysis demonstrated that ML-IAP silencing significantly decreased P19 cell proliferation while inducing cell cycle arrest and apoptosis. ML-IAP knockdown significantly induced caspase-3/8/9-mediated apoptosis in P19 cells. In addition, metabolism and stemness maintenance in P19 cells were suppressed by ML-IAP knockdown. These results indicated that ML-IAP silencing is a powerful inducer of apoptosis mediated by cell death receptors and may function as a direct activator of downstream effector caspases.
Identifiants
pubmed: 34675993
doi: 10.3892/etm.2021.10835
pii: ETM-0-0-10835
pmc: PMC8524704
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1399Informations de copyright
Copyright: © Li et al.
Références
PLoS One. 2017 Sep 18;12(9):e0185085
pubmed: 28922380
Clin Cancer Res. 2014 Jan 15;20(2):289-95
pubmed: 24270683
Oncogene. 2014 Sep 18;33(38):4697-708
pubmed: 24681955
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110
pubmed: 25510809
J Pediatr Urol. 2018 Jun;14(3):259.e1-259.e6
pubmed: 29478823
Exp Cell Res. 2007 Apr 1;313(6):1215-24
pubmed: 17291493
BMC Proc. 2013 Apr 04;7 Suppl 2:K8
pubmed: 24764487
Oncogene. 2005 Apr 28;24(19):3223-8
pubmed: 15735668
EMBO J. 1997 Dec 1;16(23):6914-25
pubmed: 9384571
Technol Cancer Res Treat. 2013 Dec;12(6):525-35
pubmed: 23617290
Oncogene. 2018 Aug;37(35):4809-4820
pubmed: 29769618
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
EMBO J. 1998 Apr 15;17(8):2215-23
pubmed: 9545235
Theranostics. 2018 Feb 5;8(6):1494-1510
pubmed: 29556337
Apoptosis. 2017 Dec;22(12):1487-1509
pubmed: 29067538
Int J Radiat Biol. 2019 Jul;95(7):912-919
pubmed: 30822194
Mol Cell Oncol. 2015 Jul 29;3(2):e1076589
pubmed: 27308600
Curr Biol. 2000 Nov 2;10(21):1359-66
pubmed: 11084335
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Apoptosis. 2017 Jul;22(7):898-919
pubmed: 28424988
FEBS Lett. 2001 Apr 20;495(1-2):56-60
pubmed: 11322947
Cancer Lett. 2013 Oct 28;340(1):113-23
pubmed: 23872274
Clin Cancer Res. 2014 Feb 1;20(3):658-67
pubmed: 24277456
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Histopathology. 2017 Jan;70(1):26-39
pubmed: 27960240
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
Cancer Cell. 2002 Feb;1(1):19-30
pubmed: 12086884
Science. 2010 Sep 17;329(5998):1492-9
pubmed: 20847263
J Pediatr Surg. 2012 Aug;47(8):1576-80
pubmed: 22901920
Int J Mol Sci. 2014 May 19;15(5):8893-930
pubmed: 24857919
FEBS J. 2016 Jan;283(2):221-31
pubmed: 26462035